Numis Securities Ltd reiterated their hold rating on shares of GW Pharmaceuticals plc (LON:GWP) in a report released on Tuesday. Numis Securities Ltd currently has a GBX 835 ($10.90) price target on the biopharmaceutical company’s stock.
Shares of GW Pharmaceuticals plc (LON:GWP) opened at 858.375 on Tuesday. GW Pharmaceuticals plc has a 12 month low of GBX 211.00 and a 12 month high of GBX 860.00. The company’s market cap is GBX 2.26 billion. The company’s 50-day moving average price is GBX 610.22 and its 200-day moving average price is GBX 538.12.
GW Pharmaceuticals plc Company Profile
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.
Receive News & Ratings for GW Pharmaceuticals plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals plc and related companies with MarketBeat.com's FREE daily email newsletter.